Compare GNL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNL | ZYME |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 2022 |
| Metric | GNL | ZYME |
|---|---|---|
| Price | $9.53 | $27.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $9.67 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.4M | 536.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.09% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $6.77 | $10.89 |
| 52 Week High | $10.04 | $29.75 |
| Indicator | GNL | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 60.65 |
| Support Level | $9.17 | $22.28 |
| Resistance Level | $9.75 | $28.49 |
| Average True Range (ATR) | 0.17 | 1.11 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 46.34 | 58.67 |
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.